Diabetes Mellitus and Vulvovaginal Candidiasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Study Completion Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical and mycological response to oral fluconazole and boric acid suppositories was assessed in patients with diabetes mellitus and vulvovaginal candidiasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vulvovaginal Candidiasis in Canadian Females

NCT04930107

Candidiasis, Vulvovaginal

RECRUITING EARLY_PHASE1

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

NCT05399641

Vulvovaginal Candidiasis

COMPLETED PHASE3

Comparison of Boric Acid vs. Terconazole in Treatment of RVVC

NCT04208555

Vulvovaginal Candidiasis

UNKNOWN NA

The Study Of Fluconazole For Vulvovaginal Candidiasis

NCT01806623

Vulvovaginal Candidiasis

COMPLETED PHASE3

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03561701

Recurrent Vulvovaginal Candidiasis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A high proportion of vulvovaginal candidiasis is due to C.glabrata that responds poorly to fluconazole therapy. We assessed the clinical relief and mycological cure in response to oral fluconazole and boric acid suppositories in patients with diabetes mellitus and vulvovaginal candidiasis given in a Randomized trial. Fluconazole was given in standard oral single dose (150 mg) fluconazole and boric acid vaginal suppositories was given in dose of 600 mg/daily for 14 uninterrupted days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Vulvovaginal Candidiasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1, Boric acid

600 mg vaginal pessaries for 14 days

Group Type ACTIVE_COMPARATOR

Boric

Intervention Type DRUG

Gelatin capsules filled with 600 mg of boric acid

2, Fluconazole

Group Type OTHER

Fluconazole

Intervention Type DRUG

150 mg oral fluconazole gives once in 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Boric

Gelatin capsules filled with 600 mg of boric acid

Intervention Type DRUG

Fluconazole

150 mg oral fluconazole gives once in 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consecutive patients with diabetes mellitus attending Endocrine OPD of All India Institute of Medical Sciences and in whom the diagnosis of vulvovaginal candidiasis was based on presence of clinical signs and symptoms and growth of Candida species on culture of high vaginal swab (HVS).

Exclusion Criteria

* Patients with vaginal discharge in whom Candida growth was not detected on fungal culture were excluded.
* Subjects also excluded were those with pregnancy,
* Sexually inactive girls,
* Age \> 65 years, renal failure and steroid therapy.
* Patients who did not give consent for pelvic examination,
* Those who were treated for any kind of vaginal discharge during the past three months and who did not comply with boric acid therapy or did not report on 15th day for repeat examination excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

66 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No